Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...
Panelists discuss how the paradigm in transplant-eligible newly diagnosed multiple myeloma (NDMM) has shifted to considering which patients should not receive quadruplet CD38-containing regimens ...
William Dale, MD, PhD, FASCO, highlighted the shift from the first geriatric oncology guidelines made in 2018 to the ...
Panelists discuss how to optimize maintenance therapy following autologous stem cell transplantation by evaluating factors such as duration, drug selection, and risk-adapted approaches to maximize ...
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback